Document:

Exhibit
10.6

 

Lorraine
J Gudas

Chairman

Department
of Pharmacology

Weill
Cornell medical College

1300
York Avenue

New
York, NY 10021

 

Dear
Dr. Gudas

 

Thank
you so much for your willingness to join the Scientific Advisory Board of Regen Biopharma Inc. the function of the Scientific
Advisory Board is to review research strategy and projects that Regen Biopharma Inc.may undertake and help identify those projects
which may lead to future developments and clinical treatments in the fields of immune- and stem cell therapy. Other areas may
be pursued as well, with advice from this SAB.

 

In
consideration for your efforts, you will receive 100,000 shares of Regen Biopharma Series A Preferred stock. Regen’s common
stock currently trades on the OTC Bulletin Board (OTCBB:RGBP). The 100,000 Series A Preferred shares are consideration for participating
in telephonic conference calls and reviewing scientific strategy and data. It is anticipated that the frequency and timing of
such calls will be approximately one call every month. Should we request an annual face to face meeting, expenses will be paid
by Regen Biopharma inc. for any out of pocket expenses associated with the meeting.

 

Additionally,
this agreement may be renewed by mutual consent each year on its anniversary date. The compensation on renewal will be another
payment of 100,000 Series A preferred stock in Regen on each anniversary that this contract is renewed by the Company.

 

It
is anticipated that members of the Scientific Advisory Board will potentially serve as primary research consultants to the Company
as such projects are undertaken. Compensation for such projects will be negotiated separately on a case-by-case basis between
the Company and the consultant.

 

Thank
you again for your participation in this exciting initiative.

 

/s/
Harry Lander

 

Harry
M. Lander

PresidentExhibit
10.7

 

October
14, 2015

Stefano
Bertuzzi, Ph.D.

American
Society for Cell biology

8120
Woodmont Avenue, Suite 750

Bethesda
MD 20814-2762

 

 

Dear
Dr. Bertuzzi

 

Thank
you so much for your willingness to join the Scientific Advisory Board of Regen Biopharma Inc. the function of the Scientific
Advisory Board is to review research strategy and projects that Regen Biopharma Inc.may undertake and help identify those projects
which may lead to future developments and clinical treatments in the fields of immune- and stem cell therapy. Other areas may
be pursued as well, with advice from this SAB.

 

In
consideration for your efforts, you will receive 100,000 shares of Regen Biopharma Series A Preferred stock. Regen’s common
stock currently trades on the OTC Bulletin Board (OTCBB:RGBP). The 100,000 Series A Preferred shares are consideration for participating
in telephonic conference calls and reviewing scientific strategy and data. It is anticipated that the frequency and timing of
such calls will be approximately one call every month. Should we request an annual face to face meeting, expenses will be paid
by Regen Biopharma inc. for any out of pocket expenses associated with the meeting.

 

Additionally,
this agreement may be renewed by mutual consent each year on its anniversary date. The compensation on renewal will be another
payment of 100,000 Series A preferred stock in Regen on each anniversary that this contract is renewed by the Company.

 

It
is anticipated that members of the Scientific Advisory Board will potentially serve as primary research consultants to the Company
as such projects are undertaken. Compensation for such projects will be negotiated separately on a case-by-case basis between
the Company and the consultant.

 

Thank
you again for your participation in this exciting initiative.

 

/s/
Harry Lander

 

Harry
M. Lander

PresidentExhibit
10.8

 

October
14, 2014

Francesco
Marincola, MD

Chief
Research Officer

Sidra
Medical and Research Center

Doha,
Quatar

 

 

Dear
Dr. Marincola

 

Thank
you so much for your willingness to join the Scientific Advisory Board of Regen Biopharma Inc. the function of the Scientific
Advisory Board is to review research strategy and projects that Regen Biopharma Inc.may undertake and help identify those projects
which may lead to future developments and clinical treatments in the fields of immune- and stem cell therapy. Other areas may
be pursued as well, with advice from this SAB.

 

In
consideration for your efforts, you will receive 100,000 shares of Regen Biopharma Series A Preferred stock. Regen’s common
stock currently trades on the OTC Bulletin Board (OTCBB:RGBP). The 100,000 Series A Preferred shares are consideration for participating
in telephonic conference calls and reviewing scientific strategy and data. It is anticipated that the frequency and timing of
such calls will be approximately one call every month. Should we request an annual face to face meeting, expenses will be paid
by Regen Biopharma inc. for any out of pocket expenses associated with the meeting.

 

Additionally,
this agreement may be renewed by mutual consent each year on its anniversary date. The compensation on renewal will be another
payment of 100,000 Series A preferred stock in Regen on each anniversary that this contract is renewed by the Company.

 

It
is anticipated that members of the Scientific Advisory Board will potentially serve as primary research consultants to the Company
as such projects are undertaken. Compensation for such projects will be negotiated separately on a case-by-case basis between
the Company and the consultant.

 

Thank
you again for your participation in this exciting initiative.

 

/s/
Harry Lander

 

Harry
M. Lander

PresidentExhibit
10.9

 

November
13, 2015

Ralph
L. Nachman, MD

Weill
Cornell Medical College

1300
York Avenue

New
York NY 10021

 

 

 

Dear
Dr. Nachman

 

Thank
you so much for your willingness to join the Scientific Advisory Board of Regen Biopharma Inc. the function of the Scientific
Advisory Board is to review research strategy and projects that Regen Biopharma Inc.may undertake and help identify those projects
which may lead to future developments and clinical treatments in the fields of immune- and stem cell therapy. Other areas may
be pursued as well, with advice from this SAB.

 

In
consideration for your efforts, you will receive 100,000 shares of Regen Biopharma Series A Preferred stock. Regen’s common
stock currently trades on the OTC Bulletin Board (OTCBB:RGBP). The 100,000 Series A Preferred shares are consideration for participating
in telephonic conference calls and reviewing scientific strategy and data. It is anticipated that the frequency and timing of
such calls will be approximately one call every month. Should we request an annual face to face meeting, expenses will be paid
by Regen Biopharma inc. for any out of pocket expenses associated with the meeting.

 

Additionally,
this agreement may be renewed by mutual consent each year on its anniversary date. The compensation on renewal will be another
payment of 100,000 Series A preferred stock in Regen on each anniversary that this contract is renewed by the Company.

 

It
is anticipated that members of the Scientific Advisory Board will potentially serve as primary research consultants to the Company
as such projects are undertaken. Compensation for such projects will be negotiated separately on a case-by-case basis between
the Company and the consultant.

 

Thank
you again for your participation in this exciting initiative.

 

/s/
Harry Lander

 

Harry
M. Lander

PresidentExhibit
10.10

 

 

August
4, 2015

 

Dear
Jonathan

 

This
letter is a follow up to our previous discussion about the Scientific Advisory Board for Regen BioPharma, Inc. The function of
the Scientific Advisory Board is to review research directions that Regen BioPharma, Inc.  may undertake, determining those
projects which may lead to future developments/advancements in the field of stem cell therapy. Other areas may be pursued as well,
with advice from this advisory board.

 

You
will receive 100,000 shares of Regen Biopharma, Series A Preferred Stock.Regen’s common stock currently trades on the OTC
Bulletin Board. The Company anticipates obtaining a stock symbol for the Series A preferred in the near future. The 100,000 shares
of Biopharma, Series A Preferred shares are consideration for participating in telephonic calls/conference calls and serving on
Regen BioPharma, Inc.’s Scientific Advisory Board. Under this SAB agreement ,the frequency and timing of such calls will
be approximately one call every month

 

Additionally,
this agreement may be renewed by mutual consent each year on its anniversary date for a maximum of 2 additional years. The compensation
on renewal will be another payment of 100,000 Series A preferred stock in Regen on each anniversary that this contract is renewed
by the Company.

 

It
is anticipated that members of the Scientific Advisory Board will potentially serve as primary research consultants to the Company
as such projects are undertaken. Compensation for such projects will be negotiated separately on a case-by-case basis between
the Company and the consultant.

 

Thank
You for your consideration.

 

David
R. Koos

Chairman
and CEO

 

P.S.:
Please sign this letter in your acceptance and fax back to me at 619-330-2328. Any usage of your name in any press releases will
be submitted to you for review and comment before being released to the public.

 

	 	 
	/s/
    Dr. Jonathan B. baell	 
	5th
    August 2015Exhibit

SEPARATION AGREEMENT AND GENERAL RELEASE

		
	Section 1.
	SEPARATION 

I, Edward G. Sloane, understand that by mutual agreement with my employer, Peoples Bank, National Association, and its parent company, affiliates and subsidiaries (collectively, “Peoples” or “Company”), my employment with Peoples is or will terminate effective November 16, 2015.  I voluntarily resign from my employment with the Company effective that date.  I am signing this Separation Agreement and General Release (“Agreement” or “General Release”) in return for the special separation benefit offered to me by Peoples, which is more than would otherwise be provided to me upon termination of my employment.  

		
	Section 2.
	SEPARATION BENEFIT 

I understand that in return for the promises and agreements set forth in this Separation Agreement, Peoples agrees as follows:

		
	a.
	Peoples will pay me severance pay equal to a continuation of salary, at my regular base pay as of the effective date of the termination of my employment, payable in accordance with standard Company payroll procedures for six (6) months. The severance pay will be subject to  required tax withholding and deductions, and will begin to be paid on the first payroll date following execution of this Agreement (subject to Section 8, below); and

		
	b.
	Peoples will not contest any application I may make for unemployment compensation benefits arising from the separation of my employment from Peoples.

I understand that (a) in no event shall any payment to me, or any part thereof, be considered earnings or compensation for any other Peoples  employment purposes, including but not limited to benefits, benefit plans, and retirement plans, (b) all bonuses, payments, or other compensation owed, of any nature, are included within the payment set forth above, and (c) no payment will be made until after the expiration of the seven-day revocation period set forth in Section 8, below.
		
	Section 3.
	COMPLETE RELEASE OF LIABILITY 

a.     General Release.  In exchange for these special severance benefits offered by Peoples, I completely release all claims I may have at this time against Peoples, its parents, subsidiaries, affiliates, insurers, administrators, benefit plans, and their successors and assigns, and their respective officers, directors, employees, and agents, in both their official and personal capacities (all of whom are collectively referred to hereafter as “Releasees”). This Release is intended to be a broad release and shall apply to any relief or benefit, no matter how denominated, including, but not limited to, claims for physical or mental injury, pain and suffering, prejudgment interest, insurance coverage, attorney fees or costs, future employment, wages, backpay, front pay, compensatory damages, or punitive damages, and all other claims, of whatever nature or kind, at law or in equity and whether known or unknown, direct or indirect, which I or any of my heirs, representatives, or assigns has, claims to have, or has ever had from the beginning of the world until the date I sign this agreement.  In addition, I agree to waive the right to receive any recovery under any charge or lawsuit filed by any other person or entity.  

         1                Employee Initials: EGS

b.    Extent of Release.  Some of the types of claims that I am releasing, although there may be others not listed here, are all claims existing (or which may exist) before the date of this Agreement and which are related to (1) any internal policies or procedures and/or benefit plans of Peoples; (2) any alleged tortious act, including without limitation any intentional tort, (3) any alleged breach of contract, (4) any alleged promissory estoppel, (5) any alleged fraud, misrepresentation or omission, (6) any alleged wrongful discharge, including without limitation, any alleged wrongful discharge in violation of public policy, (7) any alleged breach of fiduciary duty, (8) any alleged wrongful or retaliatory discharge, (9) any alleged entitlement to any insurance coverage or proceeds, including health insurance (except as set forth above), (10) any alleged entitlement to any pension, profit-sharing, or retirement benefits that are not already vested, (11) any claim to interest of any nature, including but not limited to any such claim under the common law or under Revised Code Section 1343.03(a), (12) any rights to any recovery or receipt of compensation or damages awarded as a result of any lawsuit or claims brought or asserted against Releasees by any third party or any governmental agency, (13) any alleged violation of any statutory or regulatory obligations, including any of the following laws:  (a) the Equal Pay Act, 29 U.S.C. §201, et seq.; (b) the National Labor Relations Act and the Labor Management Relations Act, 29 U.S.C. §141 et seq.; (c) the Age Discrimination in Employment Act, as amended by the Older Workers’ Benefit Protection Act and Ohio Revised Code Chapter 4112; (d) Title VII of the Civil Rights Act of 1964 including the Pregnancy Disability Act (42 U.S.C. §2000e, et seq.); (e) ERISA (the Employee Retirement Income Security Act of 1974, 29 U.S.C. §1001, et seq.); (f) COBRA; (the Consolidated Omnibus Budget Reconciliation Act of 1986, 29 U.S.C. §21161, et seq.); (g) the federal WARN Act; (h) the Family and Medical Leave Act; (i) The Americans with Disabilities Act (42 U.S.C. §12101, et seq.); (j) the United States Constitution; (k) the Civil Rights Act of 1991; (l) the Civil Rights Acts of 1866 or 1871 (42 U.S.C. §§1981, 1983, 1985, et seq.); (m) retaliation under any federal, state, or local law; (n) any claims for costs or attorney fees; (o) the Ohio laws against discrimination, and any other provision of the Ohio statutes (including but not limited to wage payment, employment discrimination, and workers’ compensation), and (p) any other Federal, State, City, County or other local law, ordinance, regulation, or common law.  
c.    Exceptions to Release.  
No part of the foregoing Release of Claims shall be interpreted to mean (a) that I am prohibited from filing a charge of discrimination (although I have released the right to any monetary recovery), or from providing information or participating as a witness in an investigation undertaken by or a proceeding before the EEOC or a state FEP agency, or (b) that I am required to pay Peoples’ attorney fees if I file a charge of discrimination or participate in an investigation or proceeding with the EEOC or a state FEP agency.  The only other claims that this release does not include are claims related to: 
		
	1.
	Claims for the payment to which I am entitled under this severance offer; 

		
	2.
	Any vested rights under Peoples’ regular employee benefit plans; 

3.     Any claims that the law states may not be waived; and
		
	4.
	Claims for unemployment compensation arising from the termination of my employment with Peoples.

         2                Employee Initials: EGS

d.    Assignment and Consequences of a Breach.  If I breach my promise in Section 3 of this General Release and file a claim or lawsuit based on what I released in this General Release, I agree to pay for all liabilities and costs incurred by Releasees, including reasonable attorneys’ fees, in defending against my lawsuit. Provided, however, that this provision shall not apply to any challenge to the validity of the ADEA waiver contained herein. 
I represent and warrant that I have not assigned or otherwise transferred (by way of subrogation, operation of law, or otherwise), any right to any other person to assert any claims of any kind or character against any of the Releasees.  I agree to indemnify and hold the Releasees harmless from and against any claims asserted by any other party against any of them, arising out of or in any way relating to any claims I may have had against the Releasees.
		
	Section 4.
	CONFIDENTIALITY 

a.Confidential Information.  In consideration of this Agreement, and in addition to any obligations that may exist under the Uniform Trade Secrets Act or other statute or common law, I agree that all Confidential Information of Peoples, or any business associate of Peoples, is to remain forever strictly confidential.  Accordingly, I agree that, except as authorized by Peoples in writing, I will not ever (a) divulge, disclose, or communicate any Confidential Information of Peoples or of its business associates to any person or entity, (b) use any Confidential Information of Peoples or of its business associates and for my own benefit or for the benefit of any third party, or (c) copy, reproduce, make notes of, appropriate, or take any Confidential Information of Peoples  or of its business associates.
“Confidential Information” as used in and for purposes of this Agreement consists of the following:  (a) all information that is considered to be a trade secret or otherwise confidential under applicable law, and (b) whether or not considered to be a trade secret by law, all information, however documented, that is related to the business and affairs of Peoples and/or its business associates, including but not limited to (1) designs, formulas, patterns, drawings, or sketches; (2) trade, design, production, technical and/or product data; (3) programs, devices, methods, processes, ideas, or techniques; (4) computer programs, listings, files, or software (including source and object codes); (5) business associate identities or lists, business history or characteristics, and information of any kind about any current or prospective business associates; (6) projects contemplated or services rendered by Peoples for any persons; (7) real estate identities, lists, pricing, and any information relating to Peoples’ real estate ventures and planning; (8) pricing policies, business plans, strategies, marketing information; (9) records or documents that are either internal to Peoples or pertaining to any business associate of Peoples; (10) data or information concerning Peoples’ operations, finances, practices, policies, contracts, strategies, plans, internal plans or practices, business plans, methods of operation, developments, techniques, improvements, or ideas; (11) information about the salary, compensation, and/or benefits provided by Peoples to employees or contractors; and (12) any other information known to Peoples personnel to be considered confidential.  Although some of this information immediately above referenced may fall within the public domain, all of the above information, for purposes of this Agreement, shall be considered Confidential Information whether or not it has been reduced to writing, and whether or not it is information that might also be in the possession of some third party.  For purposes of this Section, the term “business associate” shall mean federal, state and local governments, consultants, contractors, service providers, professional firms, customers, and affiliates, and any other persons or entities involved with Peoples  sales or operations and/or parties to agreements with Peoples .
I further agree that I will continue to be bound by any post-employment obligations contained in any agreements I have executed with Peoples.

         3                Employee Initials: EGS

		
	Section 5.
	RETURN OF INFORMATION AND PROPERTY

I agree that at or before the time of my termination, I will return to Peoples all Peoples  information and property, including all reports, maps, files, memoranda, and records; credit cards, cardkey passes; door and file keys; computer access codes; software; and other physical or personal property which I received or prepared or helped prepare in connection with my employment.  I hereby represent that I have not retained and will not retain any copies, duplicates, reproductions, or excerpts thereof. 
		
	Section 6.
	ADVICE TO CONSULT WITH ATTORNEY

I understand that I am advised to consult with an attorney before signing this General Release, if I so choose.
		
	Section 7.
	ADDITIONAL INFORMATION, PERIOD FOR REVIEW, AND     DURATION OF OFFER 

I understand and agree that I have been given a twenty-one (21) day period to review and consider this General Release. I understand that I may use as much or as little of this period of time as I wish to prior to reaching a decision regarding the signing of this General Release. I understand that if I do not sign, date, and return this General Release within twenty-one (21) days of receiving it, Peoples may decline to offer or pay the special severance payment.
		
	Section 8.
	EFFECTIVE DATE AND MY RIGHT TO REVOKE GENERAL RELEASE 

I understand that this General Release may be revoked by me at any time within seven (7) calendar days after the date I sign it.  To be effective, the revocation must be in writing and delivered to Carol Schneeberger, Executive Vice President, Chief Administrative Officer, Peoples Bank, National Association, 138 Putnam Street, Marietta, Ohio 45750, either by hand or mail within a seven (7) day period following my execution of this General Release. If delivered by mail, the rescission must be:  (a) postmarked within the seven (7) day period; (b) properly addressed as noted above; and (c) sent by Certified Mail, Return Receipt Requested. 
I understand that this General Release and my acceptance of it shall not become effective or enforceable until the seven (7) day revocation period has expired, and that no payments or other consideration will be provided to me until after the expiration of the revocation period.
		
	Section 9.
	ADDITIONAL TERMS

a.Governing Law.  It is agreed that this General Release shall be interpreted in accordance with the laws of the State of Ohio. 
b.Partial Invalidity Of The General Release.  I agree that if any term or provision of this General Release is determined by a court or other appropriate authority to be invalid, void, or unenforceable for any reason, the remainder of the terms and provisions of this General Release shall remain in full force and effect and shall in no way be affected, impaired or invalidated.  For example, I understand that if the release and waiver is invalidated for age discrimination purposes, or any reason, the release and waiver shall remain valid and effective as to all other claims.

         4                Employee Initials: EGS

c.Representations.  I agree, affirm, and represent that (1) I have not filed, caused to be filed, and presently am not a party to any claims against Peoples, (2) I have no known workplace injuries or occupational diseases, (3) I have not divulged any proprietary or confidential information of Peoples, and will continue to maintain the confidentiality of such information, (4) I have been paid and/or received all compensation, wages, bonuses, and benefits to which I was entitled during my employment, and (5) I have been granted any leaves of absence to which I was entitled, under the federal FMLA and disability laws, and in compliance with Peoples’ policies.
d.Difference of Facts.  It is understood by the parties that the facts upon which this Agreement is made, may hereafter prove to be other than or different from the facts now known by them or believed by them to be true.  Each of the parties hereto expressly accepts and assumes the risks of the facts proving to be so different, and each of the parties hereto agrees that all of the terms of this Agreement shall be in all respects effective and not subject to termination or rescission because of any such difference of facts.
e.General Terms.  I represent and affirm that no promise or agreement, or representation of any kind, has been made to me to induce me to sign this Agreement, other than as expressly stated in this written Agreement.  I agree and acknowledge that this Agreement shall not be interpreted to render me a prevailing party for any purpose, and that I fully understand the meaning and intent of this Agreement, including but not limited to its final and binding effect.  This Agreement is to be construed according to its fair meaning, and not strictly for or against any of the parties.  
f.Complete Agreement.  It is agreed that the foregoing constitutes the entire agreement between me and Peoples, and that there are no other agreements, oral or written, express or implied, relating to any matters covered by this Agreement, or any other agreement in effect and relating to any other matter whatsoever, whether or not within the knowledge or contemplation of either of the parties at the time of execution of this Agreement. 
IMPORTANT NOTICE
I acknowledge that: 
		
	•
	 I have read this General Release and I understand fully its final and binding effect; 

		
	•
	 The only promises made to me to sign this General Release are those stated herein; 

		
	•
	 I am signing this General Release voluntarily; and 

		
	•
	 I have no other claim or expectation of any additional pay or benefits incident to my Employment.

NOTICE -- PLEASE READ CAREFULLY BEFORE SIGNING
THIS SEPARATION AGREEMENT AND RELEASE IS A LEGALLY BINDING DOCUMENT WITH IMPORTANT LEGAL CONSEQUENCES, INCLUDING A RELEASE OF ALL CLAIMS, KNOWN AND UNKNOWN. YOU HAVE THE RIGHT TO REVOKE THIS AGREEMENT WITHIN SEVEN (7) CALENDAR DAYS AFTER SIGNING IT, BY DELIVERING WRITTEN NOTICE OF REVOCATION TO CAROL SCHNEEBERGER,     EXECUTIVE Vice PresidenT, cHIEF aDMINISTRATIVE OFFICER, Peoples Bank, National Association, 138 Putnam Street, Marietta, Ohio 45750. IT IS RECOMMENDED THAT YOU CONSULT YOUR OWN ATTORNEY BEFORE SIGNING THIS DOCUMENT. BY SIGNING BELOW, YOU ACKNOWLEDGE THAT YOU HAVE READ, FULLY UNDERSTAND AND VOLUNTARILY AGREE TO ALL OF THE 

         5                Employee Initials: EGS

PROVISIONS CONTAINED IN THIS SEPARATION AGREEMENT AND VOLUNTARILY AGREE TO ALL OF THE PROVISIONS CONTAINED IN THIS SEPARATION AGREEMENT AND RELEASE. 
YOU UNDERSTAND THAT, BY SIGNING THIS RELEASE AND ACCEPTING THE CONSIDERATION DESCRIBED IN THIS AGREEMENT, YOU ARE FOREVER GIVING UP THE RIGHT TO SUE RELEASEES AND ANYONE ASSOCIATED WITH THEM, FOR ANY CLAIMS, OF ANY TYPE, THAT YOU MIGHT HAVE AGAINST ANY OF THEM, BASED ON ANY EVENTS THAT HAVE OCCURRED UP TO AND INCLUDING THE MOMENT YOU SIGN THIS AGREEMENT.

	
			
	 
	 
	Peoples Bank, National Association 

	EDWARD G. SLOANE
	 
	By:  /s/ CAROL A. SCHNEEBERGER

	Employee Name (Print)
	 
	 

	 
	 
	Title:  Executive Vice President and Chief Administrative Officer

	/s/ EDWARD G. SLOANE
	 
	 

	Employee’s Signature
	 
	 

	 
	 
	 

	11/21/2015
	 
	 

	Date of Signature
	 
	 

	 
	 
	 

         6                Employee Initials: EGS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]